Factory Mutual Insurance Co. dramatically upped its stake in Regeneron Pharmaceuticals by 210.3%, acquiring an additional ...

Me filed for bankruptcy in March, seeking to sell its business at auction after a decline in consumer demand and a 2023 data breachthat exposed sensitive genetic and personal information of ...

Israel’s strike on Iran rattled markets and raised fears of oil disruption — another reminder that in today’s economy, instability is always close at hand.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the 13 Biotech Stocks with Huge Upside Potential. JPMorgan has ...

Twenty-seven states and the District of Columbia have filed a lawsuit in bankruptcy court seeking to block the sale of ...

Regeneron Pharmaceuticals just got a haircut from Wall Street, with JPMorgan Chase & Co. lowering its price target from $950 ...

Morgan Stanley has lowered its price target on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) to $755 from $958, while maintaining an Overweight rating on the stock. The revision follows what the ...

This corrects the date that the BMO Capital note was published. Shares of Regeneron Pharmaceuticals Inc. were having their worst day in more than a decade on Friday after a shocking failure in a ...

Regeneron shares rose more than 1% after its experimental ... The brunt of the effect of Trump's tariffs is yet to be felt in both economic growth and inflation, JPMorgan strategist Mislav Matejka ...

Fintel reports that on May 30, 2025, Wells Fargo downgraded their outlook for Regeneron Pharmaceuticals (NasdaqGS:REGN) from Overweight to Equal-Weight. Analyst Price Forecast Suggests 68.40% Upside ...

Currently, the analyst consensus on Regeneron is a Strong Buy with an average price target of $803.42, a 55.20% upside from current levels. In a report released today, DBS also initiated coverage ...